Friday, September 30, 2022

561.316.3330

Biotechnology News Magazine

Moderna Enlists Trial Scope – A Global Leader In Clinical Trial Disclosure and Transparency Recruitment, for Patient Recruitment

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

January 27, 2021

Moderna has enlisted the help of TrialScope Connect, an industry-first patient referral collective that connects sponsors and clinical trial recruitment partners to rapidly find, screen, and enroll clinical trial participants.

In October 2020, Moderna completed recruitment of more than 30,000 participants in the Phase 3 study of its COVID-19 Vaccine, utilizing TrialScope Connect’s platform in the final enrollment period to ensure inclusion of participants from communities that have historically been underrepresented in clinical research and are disproportionately impacted by COVID-19. The study included more than 11,000 participants from communities of color, reflecting U.S. demographics.

Unlike traditional clinical trial recruitment models, TrialScope Connect works as a collective, empowering over 75 different recruitment partners to refer patients to research sites simultaneously using a pay-for-performance model. The platform provided Moderna with real-time site performance metrics to streamline recruitment, flagging overwhelmed sites and quickly rerouting new referrals to ease congestion. With clinical research sites often juggling multiple trials, easing the burden of unqualified referrals early on is a key priority. Rather than allowing COVE Study website visitors to contact sites independently, TrialScope Connect’s embedded prescreening solution quickly prequalified leads, preventing more than 10,000 unqualified referrals from contacting already busy sites.​ ​

TrialScope Connect partners that contributed to enrollment in Moderna’s Phase 3 trial include:

“I am proud that Moderna was open to using a novel approach to clinical trial recruitment for the COVE Study,” said Melanie Ivarsson, Ph.D., Chief Development Officer at Moderna. “We were committed to ensuring that the COVE study included a diverse population including those who have been historically underrepresented in clinical research and have been disproportionately impacted by COVID-19. With TrialScope Connect, dozens of recruitment partners answered the call at once, which helped us meet our milestones.”

“When we set out to build TrialScope Connect, we knew that the old way of recruiting for clinical trials wasn’t working, but we never knew our referral network would be instrumental in supporting enrollment in this important clinical trial,” said TrialScope CEO Jeff Kozloff. “While the coronavirus pandemic has proved a monumental challenge for people across the globe, Moderna is at the forefront of the fight, and we are thrilled to play a small but important supporting role.”

 

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine